| Tumor and microenvironment evolution during immunotherapy with nivolumab N Riaz, JJ Havel, V Makarov, A Desrichard, WJ Urba, JS Sims, FS Hodi, ... Cell 171 (4), 934-949. e16, 2017 | 2002 | 2017 |
| Potential regulatory function of human dendritic cells expressing indoleamine 2, 3-dioxygenase DH Munn, MD Sharma, JR Lee, KG Jhaver, TS Johnson, DB Keskin, ... Science 297 (5588), 1867-1870, 2002 | 1327 | 2002 |
| Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment H Harlin, Y Meng, AC Peterson, Y Zha, M Tretiakova, C Slingluff, ... Cancer research 69 (7), 3077-3085, 2009 | 1243 | 2009 |
| Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines AL Cox, J Skipper, Y Chen, RA Henderson, TL Darrow, J Shabanowitz, ... Science 264 (5159), 716-719, 1994 | 1155 | 1994 |
| Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma G Erdag, JT Schaefer, ME Smolkin, DH Deacon, SM Shea, LT Dengel, ... Cancer research 72 (5), 1070-1080, 2012 | 641 | 2012 |
| An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. JC Skipper, RC Hendrickson, PH Gulden, V Brichard, A Van Pel, Y Chen, ... The Journal of experimental medicine 183 (2), 527-534, 1996 | 524 | 1996 |
| Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating … CL Slingluff Jr, GR Petroni, GV Yamshchikov, DL Barnd, S Eastham, ... Journal of Clinical Oncology 21 (21), 4016-4026, 2003 | 418 | 2003 |
| The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination? CL Slingluff Jr The Cancer Journal 17 (5), 343-350, 2011 | 378 | 2011 |
| Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial JS Weber, G Gibney, RJ Sullivan, JA Sosman, CL Slingluff, DP Lawrence, ... The Lancet Oncology 17 (7), 943-955, 2016 | 372 | 2016 |
| Conserved interferon-γ signaling drives clinical response to immune checkpoint blockade therapy in melanoma CS Grasso, J Tsoi, M Onyshchenko, G Abril-Rodriguez, ... Cancer cell 38 (4), 500-515. e3, 2020 | 339 | 2020 |
| Impact of patient distance to radiation therapy on mastectomy use in early-stage breast cancer patients AT Schroen, DR Brenin, MD Kelly, WA Knaus, CL Slingluff Jr Journal of clinical oncology 23 (28), 7074-7080, 2005 | 304 | 2005 |
| Phase I Trial of a Melanoma Vaccine with gp100280–288 Peptide and Tetanus Helper Peptide in Adjuvant: Immunologic and Clinical Outcomes CL Slingluff Jr, G Yamshchikov, P Neese, H Galavotti, S Eastham, ... Clinical Cancer Research 7 (10), 3012-3024, 2001 | 300 | 2001 |
| The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens. TL Darrow, CL Slingluff Jr, HF Seigler Journal of immunology (Baltimore, Md.: 1950) 142 (9), 3329-3335, 1989 | 285 | 1989 |
| Current status of granulocyte–macrophage colony-stimulating factor in the immunotherapy of melanoma HL Kaufman, CE Ruby, T Hughes, CL Slingluff Journal for immunotherapy of cancer 2, 1-13, 2014 | 275 | 2014 |
| Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by … T Tuting, CC Wilson, DM Martin, YL Kasamon, J Rowles, DI Ma, ... The Journal of Immunology 160 (3), 1139-1147, 1998 | 270 | 1998 |
| Terminal modifications inhibit proteolytic degradation of an immunogenic mart‐127–35 peptide: Implications for peptide vaccines LH Brinckerhoff, VV Kalashnikov, LW Thompson, GV Yamshchikov, ... International journal of cancer 83 (3), 326-334, 1999 | 268 | 1999 |
| Lethal" thin" malignant melanoma. Identifying patients at risk CL Slingluff Jr, RT Vollmer, DS Reintgen, HF Seigler Annals of surgery 208 (2), 150, 1988 | 238 | 1988 |
| Surgical Management of Regional Lymph Nodes in Patients with Melanoma Experience with 4682 Patients CL Slingluff Jr, KR Stidham, WM Ricci, WE Stanley, HF Seigler Annals of surgery 219 (2), 120-130, 1994 | 224 | 1994 |
| Anorectal melanoma: clinical characteristics and results of surgical management in twenty-four patients. CL Slingluff Jr, RT Vollmer, HF Seigler Surgery 107 (1), 1-9, 1990 | 214 | 1990 |
| Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling JT Huntington, JM Shields, CJ Der, CA Wyatt, U Benbow, CL Slingluff Jr, ... Journal of Biological Chemistry 279 (32), 33168-33176, 2004 | 207 | 2004 |
